La Jolla Pharmaceutical Company (NASDAQ:LJPC) enjoyed a 91.56% run-up in share price since hitting record low of $16.71. The stock managed -13.09% fall and now stands at $32.01 as of 02/12/2018. At recent session, the prices were hovering between $31.6 and $35.475. This company shares are 85.66% off its target price of $59.43 and the current market capitalization stands at $723.43M. The recent change has given its price a 1.04% lead over SMA 50 and -22.6% deficit over its 52-week high. The stock witnessed 5.5% gains, -8.2% declines and 4.71% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found LJPC’s volatility during a week at 7.87% and during a month it has been found around 7.8%.La Jolla Pharmaceutical Company (LJPC) Top Holders
Institutional investors currently hold around $928 million or 0% in LJPC stock. Look at its top three institutional owners. Tang Capital Management Llc owns $126.71 million in La Jolla Pharmaceutical Company, which represents roughly 17.52% of the company’s market cap and approximately 13.65% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 3,318,518 shares of the stock are valued at $122.22 million. The third largest holder is Jennison Associates Llc, which currently holds $81.78 million worth of this stock and that ownership represents nearly 11.3% of its market capitalization.
At the end of 09/30/2017 reporting period, 59 institutional holders increased their position in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by some 2,669,376 shares, 39 decreased positions by 2,179,694 and 13 held positions by 20,351,635. That puts total institutional holdings at 25,200,705 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 1,526,428 shares while 14 institutional investors sold out their entire positions totaling 724,323 shares.La Jolla Pharmaceutical Company (NASDAQ:LJPC) Insider Trades
Multiple company employees have indulged in significant insider trading. La Jolla Pharmaceutical Company disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Douglass Laura L. has sold 10,000 shares of La Jolla Pharmaceutical Company (LJPC) in trading session dated Dec. 29, 2017. These shares are worth $323,200 and were traded at $32.32 each. The SEC filing shows that Carver Jennifer performed a purchase of 1,000 shares. The COO added these shares by way of transaction on Dec. 27, 2017. The company’s shares were assimilated at $33.22 per share worth to an investment of some $33,220 on account of Carver Jennifer.
Director, 10% Owner, Tang Kevin C, purchased 149,254 common shares of La Jolla Pharmaceutical Company (LJPC) in the open market. In a transaction dated Mar. 23, 2017, the shares were bought at an average price of $33.5, giving away a sum of $5,000,009. After this purchase, 3,440,419 common shares of LJPC are directly owned by the insider, with total stake valued at $110,127,812.
In the transaction dated Mar. 03, 2017, the great number of shares acquired came courtesy the President, CEO & Secretary; Tidmarsh George F added a total of 3,000 shares at an average price of $34.17, amounting to approximately $102,510. The insider now directly owns 1,354,086 shares worth $43,344,293.La Jolla Pharmaceutical Company (LJPC) Analyst Guide
Several analysts have released their opinion on La Jolla Pharmaceutical Company (NASDAQ:LJPC), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 1 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.